Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Jemperli

(Dostarlimab)

ApprovedMonoclonal antibody

GGlaxo Dba Glaxosmithkline

Dostarlimab is used to treat certain types of cancer, specifically endometrial cancer (cancer of the uterus lining) that has a specific genetic marker called mismatch repair deficiency. It works by helping the immune system recognize and attack cancer cells.[2] Jemperli is currently approved and in use across 35 indications[4].[1]

Jemperli is one of 493 small molecule programs targeting Lung Cancer. It is currently in Approved.

35

Indications

77

Total Trials

53

Active Trials

492

Competitors

8

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Lung CancerActive, not recruiting

AdenocarcinomaRecruiting

Endometrium NeoplasmUnknown

Breast CarcinomaActive, not recruiting

Endometrial CarcinomaUnknown

Breast CancerActive, not recruiting

Pancreatic CancerRecruiting

Head and Neck Squamous Cell CarcinomaRecruiting

Multiple MyelomaActive, not recruiting

Endometrial CancerNot yet recruiting

Lung CancerPhase 3

Active, not recruiting

AdenocarcinomaPhase 2

Recruiting

Endometrium NeoplasmPreclinical

Unknown

Breast CarcinomaPhase 2

Active, not recruiting

Endometrial CarcinomaPreclinical

Unknown

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Endometrial CancerApproved

Not yet recruiting

Showing 10 of 35 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Jemperli

GGlaxo Dba Glaxosmithkline

Duragesic

Rilvegostomig

Ablavar

LLantheus Medical Imaging

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Lapatinib Plus Capecitabine

Combination NRT

UUniversity of Alabama at Birmingham

Calendula

OOHSU Knight Cancer Institute

Maxigesic

YYonsei University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Endometrial Cancer

NCT03981796

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT04446351

Q1 2027

Post-ApprovalNot yet recruiting

Endometrial Cancer

NCT06897527

Phase 2Recruiting

Endometrial Cancer

NCT04774419

Phase 2Active, not recruiting

Lung Cancer

NCT05565378

Phase 2Active, not recruiting

Multiple Myeloma

NCT04126200

Clinical

Trials by Indication[1]

Endometrial Cancer9 trials

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Recruiting· GSK logo

GSK·Phase 2·NCT07108270·30 enrolled

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Active, not recruiting·AARCAGY/ GINECO GROUP·Phase 3·NCT05201547·260 enrolled

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05819892·21 enrolled

Show 6 more trials

pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer

Not yet recruiting·UUniversity College, London·Phase 2·NCT07115927·40 enrolled

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Active, not recruiting·TTesaro, Inc.·Phase 3·NCT03981796·785 enrolled

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

Not yet recruiting·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT07013851·25 enrolled

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Not yet recruiting· GSK logo

GSK·Phase 4·NCT06897527·100 enrolled

DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer

Unknown status·GGrupo Español de Investigación en Cáncer de Ovario··NCT05728814·100 enrolled

Adjuvant Checkpoint Blockade Plus Radiation In Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSI-H) Endometrial Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04774419·62 enrolled

Ovarian Cancer4 trials

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

Terminated·TTesaro, Inc.·Phase 2·NCT03955471·41 enrolled

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Active, not recruiting·TTesaro, Inc.·Phase 3·NCT03602859·1,400 enrolled

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Completed·TTesaro, Inc.·Phase 2·NCT05751629·41 enrolled

Show 1 more trial

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT05065021·40 enrolled

Locally-advanced Rectal Cancer4 trials

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT05723562·154 enrolled

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06640049·23 enrolled

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Recruiting·—·Phase 3·NCT06762405·68 enrolled

Show 1 more trial

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

Recruiting·NNational Cancer Institute, Naples··NCT07269249·50 enrolled

Colon Cancer3 trials

Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT06830239·10 enrolled

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Recruiting·UUniversity of Iowa·Phase 2·NCT05239546·25 enrolled

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT05855200·892 enrolled

Advanced Solid Tumors3 trials

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04446351·107 enrolled

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Active, not recruiting·IiTeos Belgium SA·Phase 1/2·NCT05060432·153 enrolled

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Completed·TTesaro, Inc.·Phase 1·NCT03250832·111 enrolled

43 more indications

Non-Small Cell Lung Cancer3 trials

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed· GSK logo

GSK·Phase 2·NCT03739710·175 enrolled

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Terminated· GSK logo

GSK·Phase 2·NCT04581824·243 enrolled

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Completed· GSK logo

GSK·Phase 2·NCT06926673·62 enrolled

Neoplasms3 trials

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT05277051·152 enrolled

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Active, not recruiting·TTesaro, Inc.·Phase 1·NCT02715284·729 enrolled

A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

Terminated· GSK logo

GSK·Phase 1·NCT03843359·97 enrolled

Lung Cancer (Non-Small Cell)3 trials

A Pilot/Exploratory Translational Study to Evaluate Response to Dostarlimab and Pembrolizumab in Extracellular Vesicles (EVs) or Patient-derived Organoids (PDOs) and by Zirconium-89 Labelled Programmed Death Ligand 1 Positron Emission Tomography in Participants With Recurrent Non-small Cell Lung Cancer

Terminated· GSK logo

GSK·Preclinical·NCT06405230·2 enrolled

A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)

Active, not recruiting· GSK logo

GSK·Phase 3·NCT06472076·88 enrolled

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

Active, not recruiting· GSK logo

GSK·Preclinical·NCT04655976·758 enrolled

Efficacy and Safety2 trials

Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

Withdrawn·VVall d'Hebron Institute of Oncology·Phase 1/2·NCT06385548

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT04779151·51 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting· GSK logo

GSK·Phase 3·NCT06256588·864 enrolled

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 1/2·NCT05784012·34 enrolled

Lung Cancer2 trials

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active, not recruiting· GSK logo

GSK·Phase 2·NCT05565378·351 enrolled

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Active, not recruiting·IiOnctura·Phase 1/2·NCT06879717·45 enrolled

Pancreatic Cancer2 trials

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT04409002·18 enrolled

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

Recruiting·HHopital Foch·Phase 2·NCT06757244·35 enrolled

Multiple Myeloma1 trial

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Active, not recruiting· GSK logo

GSK·Phase 2·NCT04126200·208 enrolled

Colorectal Cancer1 trial

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Withdrawn·IIbrahim Halil Sahin·Phase 2·NCT06365970

Cervical Cancer1 trial

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Active, not recruiting·MMeghan Shea·Phase 2·NCT06238635·66 enrolled

Breast Cancer1 trial

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04837209·32 enrolled

Penile Carcinoma1 trial

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05526989·25 enrolled

Patients With Solid Tumors1 trial

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Terminated·EElevation Oncology·Phase 1·NCT05980416·88 enrolled

Microsatellite Stable1 trial

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Recruiting· GSK logo

GSK·Phase 2·NCT06567782·120 enrolled

Treatment1 trial

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Withdrawn·AAGO Research GmbH·Phase 2·NCT05126342

Metastatic1 trial

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Active, not recruiting·TTrisha Wise-Draper·Phase 2·NCT04313504·23 enrolled

Progressive Cervix Cancer1 trial

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Active, not recruiting·UUniversity of Oklahoma·Phase 2·NCT04068753·66 enrolled

Primary Peritoneal Cancer1 trial

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT04679064·427 enrolled

Brain Metastases1 trial

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05700721·120 enrolled

Selected Advanced Solid Tumors1 trial

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed· GSK logo

GSK·Phase 1·NCT02723955·829 enrolled

Cholangiocarcinoma1 trial

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Withdrawn·—·Phase 2·NCT04895046

Pediatric1 trial

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Active, not recruiting· GSK logo

GSK·Phase 1/2·NCT06521567·83 enrolled

Solid Tumors1 trial

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Terminated· GSK logo

GSK·Phase 1·NCT04544995·47 enrolled

Monotherapy1 trial

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Terminated· GSK logo

GSK·Phase 1/2·NCT06655818·4 enrolled

Cancers1 trial

PREventing Second Cancers With DOSTARlimab

Recruiting·CCentre Leon Berard·Phase 2·NCT05855811·400 enrolled

Metastatic Cancer1 trial

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Recruiting·UUNICANCER·Phase 2·NCT06333314·120 enrolled

Serous Carcinoma1 trial

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Active, not recruiting·CCasey Cosgrove·Phase 2·NCT05870761·8 enrolled

Locally Advanced Rectal Cancer (LARC)1 trial

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

Not yet recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT07381777·270 enrolled

Tumours, Gynecological1 trial

A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Recruiting· GSK logo

GSK·Preclinical·NCT06796907·305 enrolled

Ovarian Neoplasms1 trial

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)

Active, not recruiting·YYonsei University·Phase 2·NCT06023862·198 enrolled

Melanoma Stage III1 trial

PHASE II NEOADJUVANT STUDY OF PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION OF TIM-3 INHIBITOR COBOLIMAB (TSR-022) AND PD-1 INHIBITOR DOSTARLIMAB (TSR-042) IN RESECTABLE STAGE III OR OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)

Active, not recruiting·DDiwakar Davar·Phase 2·NCT04139902·58 enrolled

Lung Small Cell Carcinoma1 trial

Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04701307·48 enrolled

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial

GSK5764227 (Anti-B7H3 Antibody Drug Conjugate) Monotherapy or in Combination With Dostarlimab in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): a Multiomic Evaluation of Biomarkers of Response and Resistance (BeeHive)

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT07408063·30 enrolled

Breast Carcinoma1 trial

A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT04584255·66 enrolled

Neoplasms, Head and Neck1 trial

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06062420·316 enrolled

Malignant Skin Neoplasm1 trial

Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04387084·10 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer

Completed·MMayo Clinic·Phase 2·NCT04493060·22 enrolled

Adenocarcinoma1 trial

Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT06059495·89 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

Active, not recruiting·UUniversity of Washington·Phase 1·NCT04673448·18 enrolled

Female1 trial

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma (DICER Trial): Taiwanese Gynecologic Oncology Group (TGOG) 1012

Recruiting·CChang Gung Memorial Hospital·Phase 2·NCT07336147·45 enrolled

Rectal Neoplasms1 trial

A Phase 1b/2 Trial of Preoperative Niraparib, Dostarlimab, and Hypofractionated Radiotherapy for the Treatment of Locally-advanced Rectal Cancers.

Terminated·UUniversity of Iowa·Phase 1·NCT04926324·3 enrolled

Ovarian Clear Cell Carcinoma1 trial

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06065462·21 enrolled

Unspecified2 trials

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Withdrawn·UUniversity of Miami·Phase 2·NCT05405192

A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)

Active, not recruiting· GSK logo

GSK·Phase 2·NCT06317311·41 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 22, 2021

JEMPERLI

BLA BLA761174

Apr 22, 2021

JEMPERLI

NDA BLA761174

Apr 28, 2022

JEMPERLI

NDA BLA761174

Feb 9, 2023

JEMPERLI

NDA BLA761174

Feb 9, 2023

JEMPERLI

NDA BLA761174

Jul 31, 2023

JEMPERLI

NDA BLA761174

Mar 6, 2024

JEMPERLI

NDA BLA761174

Aug 1, 2024

JEMPERLI

NDA BLA761174

Sources

References

[1]
ClinicalTrials.gov — 77 trial records for Dostarlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jemperli drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dostarlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dostarlimab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA761174). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Antagonist[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Related News